Actively Recruiting
Safety and Tolerability Study of Single and Multiple Doses of ABBV-313 Compared to Placebo in Healthy Adults
Led by AbbVie · Updated on 2026-09-28
64
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying ABBV-313 in healthy adult volunteers to understand its safety, tolerability, how the body processes it, and immune response. This research is a Phase 1 trial focusing on both single and multiple doses of ABBV-313, a drug given by injection or infusion. The study is placebo-controlled and randomized to compare effects accurately. Participants will be assigned to one of several groups, receiving either ABBV-313 or a placebo through single or multiple doses, delivered by injection or infusion. These treatments are administered under controlled conditions to assess different dosing schedules and their impact on the body. Throughout the study, participants will be monitored for adverse events, and blood samples will be taken to measure drug levels and pharmacokinetics up to approximately 329 days. This includes monitoring how quickly and how much ABBV-313 appears in the bloodstream and how long it stays active. Safety and immune responses will be carefully followed during this time to evaluate the treatments effects.
CONDITIONS
Brief Title
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here